Beverly A Teicher

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Proteasome inhibitors
    Beverly A Teicher
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, United States Electronic address
    Biochem Pharmacol 96:1-9. 2015
  2. pmc CCR 20th anniversary commentary: In the beginning, there was PS-341
    Beverly A Teicher
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland
    Clin Cancer Res 21:939-41. 2015
  3. pmc Targeting cancer metabolism
    Beverly A Teicher
    Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 18:5537-45. 2012
  4. doi request reprint Searching for molecular targets in sarcoma
    Beverly A Teicher
    Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20852, USA
    Biochem Pharmacol 84:1-10. 2012
  5. doi request reprint Antibody conjugate therapeutics: challenges and potential
    Beverly A Teicher
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Cancer Res 17:6389-97. 2011
  6. pmc Perspective: Opportunities in recalcitrant, rare and neglected tumors
    Beverly A Teicher
    Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, Rockville, MD 20852, USA
    Oncol Rep 30:1030-4. 2013
  7. doi request reprint Bromodomain and hedgehog pathway targets in small cell lung cancer
    Gurmeet Kaur
    Molecular Pharmacology Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, USA
    Cancer Lett 371:225-39. 2016
  8. pmc Analyses of the combination of 6-MP and dasatinib in cell culture
    Gurmeet Kaur
    Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
    Int J Oncol 43:13-22. 2013
  9. pmc Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282
    Dhriti Sooryakumar
    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Mol Cancer Ther 10:1490-9. 2011

Detail Information

Publications9

  1. doi request reprint Proteasome inhibitors
    Beverly A Teicher
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, United States Electronic address
    Biochem Pharmacol 96:1-9. 2015
    ..These agents are continuing to have a major impact in their treatment of hematologic malignancies and are beginning to be explored as potential treatment agent for non-cancer indications. ..
  2. pmc CCR 20th anniversary commentary: In the beginning, there was PS-341
    Beverly A Teicher
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland
    Clin Cancer Res 21:939-41. 2015
    ..Clinical Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezomib, carfilzomib, and the oral proteasome inhibitor ixazomib (MLN9708)...
  3. pmc Targeting cancer metabolism
    Beverly A Teicher
    Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 18:5537-45. 2012
    ..These recently recognized oncogenic metabolic lesions may be selective targets for new anticancer therapeutics...
  4. doi request reprint Searching for molecular targets in sarcoma
    Beverly A Teicher
    Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20852, USA
    Biochem Pharmacol 84:1-10. 2012
    ..Discovering and developing new therapeutic approaches for these relentless diseases is critical. The detailed knowledge of sarcoma genetics may allow development of sarcoma subtype-targeted therapeutics...
  5. doi request reprint Antibody conjugate therapeutics: challenges and potential
    Beverly A Teicher
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Cancer Res 17:6389-97. 2011
    ..The time may have come for this technology to become a major contributor to improving treatment for cancer patients...
  6. pmc Perspective: Opportunities in recalcitrant, rare and neglected tumors
    Beverly A Teicher
    Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, Rockville, MD 20852, USA
    Oncol Rep 30:1030-4. 2013
    ..In conclusion, the NCI has active SPORE programs and an internal effort focused on recalcitrant, rare and neglected cancers which are generating data toward improving treatment of these difficult diseases. ..
  7. doi request reprint Bromodomain and hedgehog pathway targets in small cell lung cancer
    Gurmeet Kaur
    Molecular Pharmacology Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, USA
    Cancer Lett 371:225-39. 2016
    ..Recurrent SCLC is among the most recalcitrant cancers and drug development efforts in this cancer are a high priority. ..
  8. pmc Analyses of the combination of 6-MP and dasatinib in cell culture
    Gurmeet Kaur
    Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
    Int J Oncol 43:13-22. 2013
    ....
  9. pmc Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282
    Dhriti Sooryakumar
    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Mol Cancer Ther 10:1490-9. 2011
    ..Together, our results provide the first molecular and cellular characterization of Genz-644282 and its clinically relevant metabolites...